Nobody starts at the dose the trials measured. Semaglutide opens at 0.25 mg a week and tirzepatide at 2.5 mg, and both climb over months toward a maintenance dose many times larger. That schedule is clinical, but it casts a commercial shadow. The figure a seller quoted you may apply only to the bottom rung, which is why a seller that holds one price is worth identifying before signing up rather than after.
How the climb actually runs
The labeled semaglutide schedule for weight management moves in four-week steps: 0.25 mg, then 0.5, then 1.0, then 1.7, reaching 2.4 mg from week 17. STEP 4 used that exact shape for its run-in — 16 weeks of dose escalation followed by four weeks at the maintenance dose before anyone was randomized.[1]
Tirzepatide takes longer still. SURMOUNT-1 ran for 72 weeks and included a 20-week dose-escalation period from a 2.5 mg starting dose.[2] On either molecule, roughly the first four to five months of treatment are spent getting to the dose the headline results describe.
Two things follow from that immediately. A three-month trial of a GLP-1 is not a trial of the drug at its studied dose. And a year of treatment divides into a short escalation phase and a long maintenance phase, which is the division that decides what a pricing policy costs you.
Not everyone reaches the top
STEP 4 is unusually informative here because it published the attrition inside the climb rather than only after it. Of the 902 adults who began the open-label run-in, 803 — 89.0% — reached the 2.4 mg weekly maintenance dose and went on to be randomized.[1]
About one in nine did not get there, inside a trial, with study staff managing the escalation. That is worth holding onto when a plan is priced as though the top dose is a certainty. It is also worth holding onto in the other direction: the large majority did reach it, so a plan priced as though you will stay at the starting dose is wrong for most people.
There is a second reason the figure is useful. A prepaid quarter or year bought at a starting-dose price is a bet that the plan will keep honoring that price as the dose rises, and the schedule says the rise is the normal path. Read the prepay terms against the dose ladder rather than against the calendar.
Why the steps are slow on purpose
The escalation exists to limit gastrointestinal effects, which cluster during the climb and are the most common reason treatment stops early. Moving up faster than the labeled schedule tends to produce more of them rather than faster results, and what the trials recorded covers the rates in detail.
A dose-pricing policy outruns an opening price
Take two hypothetical plans, chosen to make the arithmetic visible rather than to describe any particular company. Plan A charges $149 a month at every dose. Plan B opens at $99 and re-prices at each step, arriving at $249 once you are on the maintenance dose.
Follow the labeled semaglutide schedule and the first year splits into four months of escalation and eight months at the top. Plan A costs $1,788 for the year. Plan B costs $396 across the first four months and $1,992 across the remaining eight, for a total of $2,388.
The shape holds whatever the specific numbers are, because escalation is a fixed fraction of a long course and the maintenance dose is the rest of it. Doubling the monthly figure for the last eight months of a year costs more than shaving a third off the first four. A seller advertising the first four months is advertising the least expensive stretch of the year.
The opening price was $50 a month lower. The year finished $600 higher. And the second year, spent entirely at the maintenance dose, widens the gap by another $1,200. This is the arithmetic that makes a lowest-price board a starting point rather than an answer: the standing rate at your eventual dose is the number that compounds.
Questions worth settling before the first charge
Four of them, and all four have checkable answers. Does the price change by dose, and if so what is it at each rung? What happens if you stay at a lower dose for longer than the schedule suggests? Is there a dose at which the plan stops escalating? And what concentration is the vial, so that a number of units means a number of milligrams?
Sellers differ widely in how much of that they publish up front, and the difference is itself informative. The individual seller write-ups record what each one states about dose pricing, and how those figures are established explains which number gets published when a company’s own pages disagree.
What the schedule does not settle
It does not settle which molecule to take. The escalation shapes are different lengths, but that is a poor basis for choosing between them next to the effect sizes and outcome data in the evidence comparison.
It also does not transfer cleanly to what most sellers actually dispense. The schedules above belong to approved products. A compounded preparation may be supplied at a concentration and on a cadence set by the prescriber rather than by a label, a distinction laid out in the compounding article.
So the schedule is a map of the terrain rather than an itinerary. It tells you that treatment has a short expensive-to-misjudge beginning and a long plateau, that most people reach the plateau and some do not, and that a year’s cost is decided mostly by the plateau. The dose you end up on, and what it costs at that dose, is a question for the seller and the prescriber together. Ask it in month one, not in month five when the invoice changes.